The management of endometrial cancer

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue 2, 1997, Pages 127-134

  Lawton, Frank ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

CANCER STAGING; CANCER SURVIVAL; CYTOLOGY; ENDOMETRIUM CANCER; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LYMPHADENECTOMY; PREDICTION; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE;

ENDOMETRIAL NEOPLASMS; FEMALE; HORMONES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM STAGING; RISK FACTORS;

EID: 0031043077     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb11031.x     Document Type: Review

References (44)

1. Lewis BV, Stallworthy JA, Cowdell R. Adenocarcinoma of the body of the uterus. J Obstet Gynaecol Br Comnwlth 1970; 77: 433–448.
2. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 1987; 60: 2035–2041.
3. Gal D, Recio FO, Zamurovic D. The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer 1992; 69: 200–202.
4. Lanciano RM, Corn BW, Schultz DJ, Kramer KA, Rosenblum N, Hogan WM. The justification for a surgical staging system in endometrial carcinoma. Radiother Oncol 1993; 28: 189–196.
5. Kadar N, Malfetano JH, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol 1992; 80: 655–659.
6. Elliott P, Green D, Coates A et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer, Int J Gynecol Cancer 1994; 4: 84–93.
7. Kucera H, Vaura N, Weghaupt K. Benefit of external irradiation in pathologic stage I endometrial carcinoma: A prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 1990; 38: 99–104.
8. Piver MS, Hempling RE. A prospective trial of postoperative vaginal radium/cesium for grade 1–2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma. Cancer 1990; 66: 1133–1138.
9. Chen S. Operative treatment of stage I endometrial carcinoma with deep myometrial invasion and/or grade 3 tumor surgically limited to the corpus uteri. Cancer 1989; 63: 1843–1845.
10. COSA-NZ-UK Endometrial cancer study groups. Pelvic lymphadenectomy in high risk endometrial cancer. Int J Gynecol Cancer 1996; 6: 102–107.
11. DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrence patterns in stage I endometrial cancer. Am J Obstet Gynecol 1985; 151: 1009–1015.
12. Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: Survival comparisons with and without pelvic node sampling. Gynecol Oncol 1995; 56: 29–33.
13. Homesley HD, Kadar N, Barrett RJ, Lentz SS. Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. Am J Obstet Gynecol 1992; 167: 1225–1230.
14. Larson DM, Johnson K, Olson KA. Pelvic and paraaortic lymphadenectomy for surgical staging of endometrial cancer. Morbidity and mortality. Obstet Gynecol 1992; 79: 998–1001.
15. Lampe B, Kurzl R, Hantschmann P. Prognostic factors that predict pelvic node metastasis from endometrial carcinoma. Cancer 1994; 74: 2502–2508.
16. Del Maschio A, Vanzulli A, Sironi S et al. Estimating the depth of myometrial involvement by endometrial carcinoma. Efficacy of transvaginal sonography vs MR imaging. AJR 1993; 160: 533–538.
17. Minderhoud-Bassie W, Treurniet FEE, Koops W, Chadwa-Adwani S, Hage J, Huikeshoven JM. Magnetic resonance imaging [MRI] in endometrial carcinoma; preoperative estimation of depth of myometrial invasion. Acta Obstet Gynecol Scand 1995; 74: 827–831.
18. Fishman DA, Roberts KB, Chambers JT, Kohorn EI, Schwartz PE, Chambers SK. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol 1996; 61: 189–196.
19. Landgren RD, Fletcher GH, Delclos L, Wharton JT. Irradiation of endometrial cancer in patients with medical contraindications to surgery or with unresectable lesions. AJR 1976; 126: 148–154.
20. Morrow CP, DiSaia PJ, Townsend DE. Current management of endometrial carcinoma. Obstet Gynecol 1973; 42: 399–406.
21. Goff B, Goodman A, Muntz HG, Fuller AF, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994; 52: 237–240.
22. Jones HW. Treatment of adenocarcinoma of the endometrium. Obstet Gynecol Survey 1975; 30: 147–169.
23. Aalders JG, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 1980; 56: 419–426.
24. Lotocki RJ, Copeland LJ, De Petrillo AD, Muirhead W. Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am J Obstet Gynecol 1983; 146: 141–146.
25. Joelsson I, Sandri A, Kottmeier HL. Carcinoma of the uterine corpus: a retrospective survey of individualised therapy. Acta Radiol 1973; 334: 3–7.
26. Lentz SS. Advanced and recurrent endometrial carcinoma: hormonal therapy Sem Oncol 1994; 21: 100–106.
27. Kaupila A. Progestin therapy of endometrial, breast and ovarian carcinoma. Acta Obstet Gynecol Scand 1984; 63: 441–450.
28. Kohorn EG. estagens and endometrial carcinoma. Gynecol Oncol 1976; 4: 398–411.
29. Vergote I, Kjorstad J, Abeler V, Kolstad P. Arandomised trial of adjuvant progestogens in early endometrial cancer. Cancer 1989; 64: 1011–1016.
30. Van Leeuwen FE, Benrandt J, Coebergh JWJ et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448–452.
31. Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminatedendometrial cancer. Obstet Gynecol 1982; 59: 225–228.
32. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. A phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979; 63: 21–27.
33. Burke TW, Gershenson DM, Morris M et al. Postoperative adjuvant cisplatin, doxorubicin and cyclophosphamide [PAC] chemotherapy in women with high risk endometrial carcinoma. Gynecol Oncol 1994; 55: 47–50.
34. Smith MR, Peters WAHI, Drescher CW. Cisplatin, doxoribicin and cyclophosphamide followed by radiotherapy in high risk endometrial carcinoma. Am J Obstet Gynecol 1994; 170: 1677–1682.
35. Creasman WT, Rutledge F. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol 1971; 110: 773–781.
36. Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgico-pathologic risk factors and outcome in clinical stage 1 and II carcinoma of the nedometrium. A Gynecologic Oncology Group study. Gynecol Oncol 1991; 40: 55–65.
37. Polish RA, Twiggs LB, Adcock LL, SAvage JE, Levitt SH, Prem KA. Paraortic lymph node radiotherapy in cancer of the uterine corpus. Obstet Gynecol 1985; 65: 251–256.
38. Hendrickson MR, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93–108.
39. Jeffrey JF, Krepart GV, Lotocki RJ. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol 1986; 67: 670–674.
40. Frank AH, Tseng PC, Haffty BG et al. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer 1991; 68: 1516–1519.
41. Sears JD, Greven KM, Hoen HM, Randall ME. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 1994; 74: 1303–1308.
42. Curran WJ, Whittington R, Peters AJ, Fanning J. Vaginal recurrences of endometrial carcinoma: the prognostic value of staging by a primary vaginal carcinoma system. Int J Radiat Oncol Biol Phys 1988; 15: 803–808.
43. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996; 60: 288–291.
44. Childers JM, Brzechffa PR, Hatch KD, Surwit EA. Laparoscopically-assisted surgical staging [LASS] of endometrial cancer. Gynecol Oncol 1993; 51: 33–38.